Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept and methotrexate monotherapy or combination therapy in psoriatic arthritis
2014-004869-24Phase 3Completed
- Sponsor
- Amgen
- Start
- Nov 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in psoriatic arthritis (PsA) comparing Enbrel + methotrexate, Enbrel monotherapy and Methotrexate monotherapy (3 arms). Primary endpoint: American College of Rheumatology 20 response at week 24. Started Nov 2015; status: completed.
02
Drugs
etanerceptmethotrexate
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2014-004869-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004869-24.